Andrew Spaventa - 02 Nov 2026 Form 4 Insider Report for Aspen Neuroscience, Inc. (ASPE)

SEC form
4
Accepted by SEC
02 Nov 2026, 21:05:19 UTC
Prior SEC filing
29 Oct 2026
Source filing
View source filing
Filing notes and source

Key filing fact

Andrew Spaventa filed Form 4 for Aspen Neuroscience, Inc. (ASPE) on 02 Nov 2026.

Key facts

  • This page summarizes Andrew Spaventa's Form 4 filing for Aspen Neuroscience, Inc. (ASPE).
  • 4 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 02 Nov 2026, 21:05.

Change

  • Previous filing in this sequence was filed on 29 Oct 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001859701 Primary reporting owner

Spaventa Andrew

Relationship
Director

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ASPE transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+70,194
Change %
Price
Shares after
70,194
Date
02 Nov 2026
Ownership
See Footnote 2.
Footnotes
F1, F2
ASPE transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+180,221
Change %
Price
Shares after
180,221
Date
02 Nov 2026
Ownership
See Footnote 3.
Footnotes
F1, F3
ASPE holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
7,747
Date
02 Nov 2026
Ownership
Direct
ASPE holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
49,914
Date
02 Nov 2026
Ownership
See Footnote 4.
Footnotes
F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ASPE transaction Derivative

Series Seed Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares
-70,194
Change %
-100%
Price
Shares after
0
Date
02 Nov 2026
Ownership
See Footnote 2.
Underlying class
Common Stock
Underlying amount
70,194
Exercise price
Footnotes
F1, F2
ASPE transaction Derivative

Series C Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares
-180,221
Change %
-100%
Price
Shares after
0
Date
02 Nov 2026
Ownership
See Footnote 3.
Underlying class
Common Stock
Underlying amount
180,221
Exercise price
Footnotes
F1, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Each share of Series Seed Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 1-for-9.8821 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

Footnote F2

Securities held by Axon Holdings, LLC Series XIII - Aspen Seed, of which Mr. Spaventa is a managing partner.

Footnote F3

Securities held by Axon Holdings, LLC Series XXI - Aspen C, of which Mr. Spaventa is a managing partner.

Footnote F4

Shares of Common Stock held by The Andrew K. Spaventa Living Trust Dated April 9, 2014.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .